In the wake of modern-era blockbuster successes such as Neulasta, Neupogen, and Enbrel, it’s often forgotten that Amgen was founded in 1980 as a forward-minded biotech company (Applied Molecular Genetics). Given this background, it shouldn’t come as much of a surprise that today’s Amgen remains one of the most tech-forward players in Big Pharma.
executive director, Amgen Digital Health at Amgen
Jorden leads the company’s digital charge, directing Amgen’s myriad health tech pilots and overseeing implementation of any number of initiatives. His charge includes assessing the potential of buzzy tech (AI, big data, sensors, and the like) to either mitigate or solve unmet patient needs.
Jorden arrived at Amgen in 2014, initially serving as a strategy and business performance director in the company’s results delivery office. In that role, he oversaw strategy for Amgen’s transformation program. Prior to that, he held several positions at General Electric, most recently financial controller of a GE Aviation division based in Singapore.